Vir Biotechnology, Inc. Effective Tax Rate
Vir Biotechnology, Inc. (VIR) reported Effective Tax Rate of 0.20% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-08-05
- Vir Biotechnology, Inc. effective income tax rate reconciliation, percent for the quarter ending 2026-06-30 was 0.20%.
- Vir Biotechnology, Inc. effective income tax rate reconciliation, percent for the quarter ending 2026-03-31 was -0.10%.
- Vir Biotechnology, Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-09-30 was -0.10%.
- Vir Biotechnology, Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-06-30 was -0.20%, a 118.18% decline year-over-year.
- Vir Biotechnology, Inc. effective income tax rate reconciliation, percent for fiscal 2025 was -0.03%, a 115.00% decline from fiscal 2024.
- Vir Biotechnology, Inc. effective income tax rate reconciliation, percent for fiscal 2024 was 0.20%, a 90.48% decline from fiscal 2023.
- Vir Biotechnology, Inc. effective income tax rate reconciliation, percent for fiscal 2023 was 2.10%, a 93.35% decline from fiscal 2022.
- Vir Biotechnology, Inc. effective income tax rate reconciliation, percent for fiscal 2022 was 31.60%, a 710.26% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.20% 10-Q · filed 2026-08-05 | -0.80% 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | -0.10% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -0.03% 10-K · filed 2026-02-23 | |||
| 2025-09-30 | -0.10% 10-Q · filed 2025-11-05 | -0.10% 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | -0.20% 10-Q · filed 2026-08-05 | -0.10% 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 0.20% 10-K · filed 2026-02-23 | |||
| 2024-09-30 | -0.10% 10-Q · filed 2025-11-05 | 0.30% 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 1.10% 10-Q · filed 2025-08-06 | 0.60% 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -0.40% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 2.10% 10-K · filed 2026-02-23 | |||
| 2023-09-30 | 1.90% 10-Q · filed 2024-11-04 | 1.60% 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | 1.40% 10-Q · filed 2024-08-01 | 1.50% 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | 1.60% 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | 31.60% 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 19.50% 10-Q · filed 2023-11-03 | 31.80% 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | 67.30% 10-Q · filed 2023-08-04 | 35.80% 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | 43.70% 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 3.90% 10-K · filed 2024-02-26 | |||
| 2021-09-30 | 0.30% 10-Q · filed 2022-11-03 | 14.90% 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | 0.10% 10-Q · filed 2022-08-09 | -0.20% 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | 0.10% 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 0.00% 10-K · filed 2023-02-28 | |||
| 2019-12-31 | -0.10% 10-K · filed 2022-02-28 | |||
| 2018-12-31 | 0.40% 10-K · filed 2021-02-25 | |||
| 2017-12-31 | 13.50% 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |